Search

Displaying results 4061 - 4070 of 7059 in total
  1. Drug

    Sertindole

    go.drugbank.com/drugs/DB06144
    ApprovedWithdrawn

    It is a phenylindole derivative used in the treatment of schizophrenia. … Sertindole, a neuroleptic, is one of the newer antipsychotic medications available. Serdolect is developed by the Danish pharmaceutical company H. Lundbeck.

    Categories: Dopamine D2 Receptor Antagonists
  2. Drug

    Thiethylperazine

    go.drugbank.com/drugs/DB00372
    ApprovedInvestigationalWithdrawn

    A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins.

    Categories: Dopamine D2 Receptor Antagonists
  3. Drug

    Plozasiran

    go.drugbank.com/drugs/DB18997
    ApprovedInvestigational

    Plozasiran (ARO-APOC3) is a small interfering RNA (siRNA) that degrades apolipoprotein C-III (apoC-III) mRNA by RNA interference. … [L45864] Plozasiran was first approved by the FDA on November 18th, 2025, to reduce triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS).[L54603]

  4. Drug

    Carglumic acid

    go.drugbank.com/drugs/DB06775
    ApprovedInvestigational

    Carglumic acid is a drug used for the treatment of hyperammonemia in patients with a deficiency in N-acetyl glutamate synthase. … Food and Drug Administration (FDA) on 18 March 2010.

  5. Drug

    Ezogabine

    go.drugbank.com/drugs/DB04953
    ApprovedWithdrawn

    FDA approved in June 10, 2011 under the name of ezogabine. … It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures

  6. Drug

    Pindolol

    go.drugbank.com/drugs/DB00960
    ApprovedInvestigational

    [A231064] Pindolol was granted FDA approval on 3 September 1982.[L32348] … Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension.

  7. Drug

    Ganirelix

    go.drugbank.com/drugs/DB06785
    ApprovedInvestigational

    Ganirelix is a synthetic decapeptide and a competitive gonadotropin-releasing hormone (GnRH) antagonist. Derived from endogenous GnRH, ganirelix has amino acid substitutions. … [A252195] Ganirelix was first approved by the FDA on July 29, 1999.[L43070]

  8. Drug

    Perampanel

    go.drugbank.com/drugs/DB08883
    ApprovedInvestigational

    Perampanel is a noncompetitive AMPA glutamate receptor antagonist. … The FDA label includes an important black-boxed warning of serious or life-threatening behavioral and psychiatric reactions in patients taking Fycompa™.

  9. Drug

    Plosaracetam

    go.drugbank.com/drugs/DB21594
    Investigational

    Plosaracetam has a monoisotopic molecular weight of 330.05 Da. … Plosaracetam is a small molecule drug. The usage of the INN stem '-racetam' in the name indicates that Plosaracetam is a piracetam type amide type nootrope agent.

  10. Drug

    Icalcaprant

    go.drugbank.com/drugs/DB21651
    Investigational

    Icalcaprant has a monoisotopic molecular weight of 406.2 Da. … Icalcaprant is a small molecule drug. The usage of the INN stem '-caprant' in the name indicates that Icalcaprant is a kappa-opioid receptor (KOR) antagonist.